View More View Less
  • 1 Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
  • 2 Friedrich Loeffler Institute for Medical Microbiology, Greifswald, Germany
  • 3 Center for Behavioral Brain Sciences, Magdeburg, Germany

Application of the proteasome inhibitor Bortezomib for the treatment of haematopoietic malignancies such as multiple myeloma significantly improves the average overall survival of patients. However, one of the most severe side effects is the development of peripheral neuropathies caused by neurotoxic effects of Bortezomib limiting its therapeutic efficacy. With ONX-0914 a specific inhibitor of the β5i (LMP7)-immunosubunit containing proteasomes was developed that targets exclusively the proteasome subtypes mainly expressed in immune cells including B lymphocytes as the origin of multiple myeloma. Furthermore, immunosubunitspecific inhibitors have been shown to be promising tools for the therapy of autoimmune disorders. In the presented study, we analysed the concentration-dependent impact of both inhibitors on primary neurons regarding survival rate, morphological changes, and overall viability. Our results clearly demonstrate that ONX-0914, compared to Bortezomib, is less neurotoxic suggesting its potential as a putative antineoplastic drug and as a candidate for the treatment of autoimmune disorders affecting the peripheral and/or central nervous system.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1.

    Kane RC , Bross PF, Farrell AT, Pazdur R: Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist 8, 508513 (2003)

    • Search Google Scholar
    • Export Citation
  • 2.

    Crawford LJ , Walker B, Irvine AE: Proteasome inhibitors in cancer therapy. J Cell Commun Signal 5, 101110 (2011)

  • 3.

    Dou QP , Zonder JA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 14, 517536 (2014)

    • Search Google Scholar
    • Export Citation
  • 4.

    Richardson PG , Hideshima T, Mitsiades C, Anderson K: Proteasome inhibition in hematologic malignancies. Ann Med 36, 304314 (2004)

  • 5.

    Adams J : The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4, 349360 (2004)

  • 6.

    Landgren O , Iskander K: Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes. J Intern Med [Epub ahead of print], doi: 10.1111/joim.12590 (2017)

    • Search Google Scholar
    • Export Citation
  • 7.

    Dou QP , Zonder JA: Overview of proteasome inhibitorbased anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets 14, 517536 (2014)

    • Search Google Scholar
    • Export Citation
  • 8.

    Almond JB , Cohen GM: The proteasome: a novel target for cancer chemotherapy. Leukemia 16, 433443 (2002)

  • 9.

    Glickman MH , Ciechanover A: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82, 373428 (2002)

    • Search Google Scholar
    • Export Citation
  • 10.

    Goldberg AL , Akopian TN, Kisselev AF, Lee DH, Rohrwild M: New insights into the mechanisms and importance of the proteasome in intracellular protein degradation. Biol Chem 378, 131140 (1997)

    • Search Google Scholar
    • Export Citation
  • 11.

    Adams J : Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr Opin Chem Biol 6, 493500 (2002)

    • Search Google Scholar
    • Export Citation
  • 12.

    Adams J : The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417421 (2004)

  • 13.

    Hideshima T , Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61, 30713076 (2001)

    • Search Google Scholar
    • Export Citation
  • 14.

    Mateos MV , San Miguel JF: Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 20, 701715 (2007)

  • 15.

    Viatour P , Merville M-P, Bours V, Chariot A: Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation. Trends Biochem Sci 30, 4352 (2005)

    • Search Google Scholar
    • Export Citation
  • 16.

    Richardson PG , Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau J-L, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352, 24872498 (2005)

    • Search Google Scholar
    • Export Citation
  • 17.

    Oerlemans R , Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GL, Dijkmans BAC, Scheper RJ, Jansen G: Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 24892499 (2008)

    • Search Google Scholar
    • Export Citation
  • 18.

    Verbrugge SE , Al M, Assaraf YG, Niewerth D, Meerloo J van, Cloos J, Veer M van der, Scheffer GL, Peters GJ, Chan ET, Anderl JL, Kirk CJ, Zweegman S, Dijkmans BA, Lems WF, Scheper RJ, Gruijl TD de, Jansen G: Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors. Exp Hematol Oncol 2, 2 (2013)

    • Search Google Scholar
    • Export Citation
  • 19.

    Banach M , Juranek JK, Zygulska AL: Chemotherapyinduced neuropathies-a growing problem for patients and health care providers. Brain Behav 7, e00558 (2017)

    • Search Google Scholar
    • Export Citation
  • 20.

    Bruna J , Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, Silverman L, Navarro X: Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. Exp Neurol 223, 599608 (2010)

    • Search Google Scholar
    • Export Citation
  • 21.

    Brown MG , Driscoll J, Monaco JJ: Structural and serological similarity of MHC-linked LMP and proteasome (multicatalytic proteinase) complexes. Nature 353, 355357 (1991)

    • Search Google Scholar
    • Export Citation
  • 22.

    Monaco JJ , McDevitt HO: The LMP antigens: A stable MHC-controlled multisubunit protein complex. Hum Immunol 15, 416426 (1986)

  • 23.

    Yang Y , Waters JB, Früh K, Peterson PA: Proteasomes are regulated by interferon gamma: implications for antigen processing. Proc Natl Acad Sci U S A 89, 49284932 (1992)

    • Search Google Scholar
    • Export Citation
  • 24.

    Ferrington DA , Gregerson DS: Immunoproteasomes: Structure, function, and antigen presentation. Prog Mol Biol Transl Sci 109, 75112 (2012)

    • Search Google Scholar
    • Export Citation
  • 25.

    Seifert U , Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schröter F, Prozorovski T, Lange N, Steffen J, Rieger M, Kuckelkorn U, Aktas O, Kloetzel P-M, Krüger E: Immunoproteasomes preserve protein homeostasis upon interferoninduced oxidative stress. Cell 142, 613624 (2010)

    • Search Google Scholar
    • Export Citation
  • 26.

    Yun YS , Kim KH, Tschida B, Sachs Z, Noble-Orcutt KE, Moriarity BS, Ai T, Ding R, Williams J, Chen L, Largaespada D, Kim D-H: mTORC1 coordinates protein synthesis and immunoproteasome formation via PRAS40 to prevent accumulation of protein stress. Mol Cell 61, 625639 (2016)

    • Search Google Scholar
    • Export Citation
  • 27.

    Mishto M , Liepe J, Textoris-Taube K, Keller C, Henklein P, Weberruß M, Dahlmann B, Enenkel C, Voigt A, Kuckelkorn U, Stumpf MPH, Kloetzel PM: Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur J Immunol 44, 35083521 (2014)

    • Search Google Scholar
    • Export Citation
  • 28.

    Toes REM , Nussbaum AK, Degermann S, Schirle M, Emmerich NPN, Kraft M, Laplace C, Zwinderman A, Dick TP, Müller J, Schönfisch B, Schmid C, Fehling H-J, Stevanovic S, Rammensee HG, Schild H: Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J Exp Med 194, 112 (2001)

    • Search Google Scholar
    • Export Citation
  • 29.

    Basler M , Mundt S, Muchamuel T, Moll C, Jiang J, Groettrup M, Kirk CJ: Inhibition of the immunoproteasome ameliorates experimental autoimmune encephalomyelitis. EMBO Mol Med 6, 22638 (2014)

    • Search Google Scholar
    • Export Citation
  • 30.

    Ebstein F , Kloetzel P-M, Krüger E, Seifert U: Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci CMLS 69, 25432558 (2012)

    • Search Google Scholar
    • Export Citation
  • 31.

    Muchamuel T , Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C, Sylvain C, Ring ER, Shields J, Jiang J, J, Shwonek P, Parlati F, Demo SD, Bennett MK, Kirk CJ, Groettrup M: A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15, 781787 (2009)

    • Search Google Scholar
    • Export Citation
  • 32.

    Kalim KW , Basler M, Kirk CJ, Groettrup M: Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation. J Immunol 189, 41824193 (2012)

    • Search Google Scholar
    • Export Citation
  • 33.

    Hensley SE , Zanker D, Dolan BP, David A, Hickman HD, Embry AC, Skon CN, Grebe KM, Griffin TA, Chen W, Bennink JR, Yewdell JW: Unexpected role for the immunoproteasome subunit LMP2 in antiviral humoral and innate immune responses. J Immunol 184, 41154122 (2010)

    • Search Google Scholar
    • Export Citation
  • 34.

    Basler M , Mundt S, Bitzer A, Schmidt C, Groettrup M: The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol 33, S749 (2015)

    • Search Google Scholar
    • Export Citation
  • 35.

    Liu H , Wan C, Ding Y, Han R, He Y, Xiao J, Hao J: PR-957, a selective inhibitor of immunoproteasome subunit low-MW polypeptide 7, attenuates experimental autoimmune neuritis by suppressing Th 17-cell differentiation and regulating cytokine production. FASEB J 31, 17561766 (2017)

    • Search Google Scholar
    • Export Citation
  • 36.

    Basler M , Dajee M, Moll C, Groettrup M, Kirk CJ: Prevention of experimental colitis by a selective inhibitor of the immunoproteasome. J Immunol Baltim Md 1950 185, 634641 (2010)

    • Search Google Scholar
    • Export Citation
  • 37.

    Vachharajani N , Joeris T, Luu M, Hartmann S, Pautz S, Jenike E, Pantazis G, Prinz I, Hofer MJ, Steinhoff U, Visekruna A: Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7. Oncotarget [Epub ahead of print], doi: 10.18632/oncotarget.14579 (2017)

    • Search Google Scholar
    • Export Citation
  • 38.

    Zaiss DMW , Bekker CPJ, Grone A, Lie BA, Sijts AJAM: Proteasome immunosubunits protect against the development of CD8 T cell-mediated autoimmune diseases. J Immunol 187, 23022309 (2011)

    • Search Google Scholar
    • Export Citation
  • 39.

    Wehenkel M , Ban J-O, Ho Y-K, Carmony KC, Hong JT, Kim KB: A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice. Br J Cancer 107, 5362 (2012)

    • Search Google Scholar
    • Export Citation
  • 40.

    Kuhn DJ , Hunsucker SA, Chen Q, Voorhees PM, Orlowski M, Orlowski RZ: Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood 113, 4667 (2009)

    • Search Google Scholar
    • Export Citation
  • 41.

    Banker G , Goslin K: Developments in neuronal cell culture. Nature 336, 185186 (1988)

  • 42.

    McLean IW , Nakane PK: Periodate-lysine-paraformaldehyde fixative. A new fixation for immunoelectron microscopy. J Histochem Cytochem 22, 107783 (1974)

    • Search Google Scholar
    • Export Citation
  • 43.

    Staff NP , Podratz JL, Grassner L, Bader M, Paz J, Knight AM, Loprinzi CL, Trushina E, Windebank AJ: Bortezomib alters microtubule polymerization and axonal transport in rat dorsal root ganglion neurons. NeuroToxicology 39, 124131 (2013)

    • Search Google Scholar
    • Export Citation
  • 44.

    Zheng H , Xiao WH, Bennett GJ: Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol 238, 225234 (2012)

    • Search Google Scholar
    • Export Citation

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Nov 2020 0 9 6
Dec 2020 0 3 3
Jan 2021 0 9 6
Feb 2021 0 7 6
Mar 2021 0 7 2
Apr 2021 0 7 6
May 2021 0 0 0